FGFR2 and infantile convulsions and choreoathetosis: In 2019, the US Food and Drug Administration (FDA) granted accelerated approval for pemigatinib, an FGFR2 inhibitor, as the first targeted therapy for locally advanced or metastatic iCCA with FGFR2 fusions or rearrangement [18].